EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment – a qualitative analysis

Laura Flight iD, Fatima Salih iD, Shane D Collins, Phyo Aung, Michael Coory, Daniel A Ollendorf, Marina Richardson iD, Zoe Garrett iD

International Journal of Technology Assessment in Health Care · 2026 · 42 (1)

DOI: 10.1017/s0266462326103791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, online erschienen am 07.08.2026. Verfasst von Laura Flight und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Excellence, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Cost-Benefit Analysis, Cost-Effectiveness Analysis, Biomarkers. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The use of surrogate endpoints poses challenges to health technology assessment (HTA) agencies and payers when informing the clinical and cost-effectiveness of health technologies. Decision makers often need to make recommendations in the absence of well-established evidence on their validation, particularly when the surrogate endpoint is novel without clear links to the longer-term outcome. This study explored the guidance needs of HTA agencies and identified how they have considered and dealt with surrogate endpoints in cost-effectiveness analysis.

Methods

A qualitative study was used to explore the professional experiences of international HTA staff and their collaborators. Data were collected using three focus groups with 29 participants representing 20 HTA agencies or associated organizations. Framework analysis was used to identify themes from the transcripts.

Results

HTA agencies frequently see submissions featuring surrogate endpoints. Issues they face include definitional concerns, absent or weak evidentiary links, and resource-intensive validation methods. Versatile guidance that is mindful of these challenges, such as those faced with rare diseases, is required. This would help to clarify expectations and help ascertain the required information from industry for economic modeling, on how to present the uncertainty arising from surrogate endpoints, and how to appropriately report the findings.

Conclusions

Decision making using surrogate endpoints is a frequent and challenging problem faced by HTA agencies. These results provide the first-hand experiences and reflect the needs of HTA agencies globally. The resulting recommendations and considerations for the use of surrogate endpoints in economic modeling should benefit HTA agencies moving forward.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalCost-Benefit AnalysisCost-Effectiveness AnalysisBiomarkersEndpoint DeterminationQualitative ResearchHumansFocus GroupsDecision Making

Stichwörter der Autor:innen

health economic modelhealth technology assessmentsurrogate endpointsurrogate outcome

Substanzen

Biomarkers

Autor:innen und Institutionen

  • National Institute for Health and Care Excellence, UK.
  • Department of Epidemiology and Preventive Medicine, Monash University, Australia.
  • Mater Research Institute, Faculty of Medicine, University of Queensland, Australia.
  • Institute for Clinical and Economic Review, USA.

ORCID-Profile: Laura Flight, Fatima Salih, Marina Richardson, Zoe Garrett

Zitieren

APA

Flight, L., Salih, F., Collins, S. D., Aung, P., Coory, M., Ollendorf, D. A., Richardson, M., & Garrett, Z. (2026). Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment – a qualitative analysis. International Journal of Technology Assessment in Health Care, 42(1). https://doi.org/10.1017/s0266462326103791

Vancouver

Flight L, Salih F, Collins SD, Aung P, Coory M, Ollendorf DA, et al. Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment – a qualitative analysis. International Journal of Technology Assessment in Health Care. 2026;42(1). doi:10.1017/s0266462326103791

BibTeX
@article{Flight2026,
  author = {Flight, Laura and Salih, Fatima and Collins, Shane D and Aung, Phyo and Coory, Michael and Ollendorf, Daniel A and Richardson, Marina and Garrett, Zoe},
  title = {Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment – a qualitative analysis},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2026},
  volume = {42},
  number = {1},
  doi = {10.1017/s0266462326103791}
}
Kostenlos starten →